<DOC>
	<DOCNO>NCT01151358</DOCNO>
	<brief_summary>MERIT-NHL addendum International Registry Radioimmunotherapy ( RIT registry ) pool clinical data patient suffer non-Hodgkin´s lymphoma also include documentation respective FDG-PET CT-image file online archive . Based documented clinical imaging data , MERIT study group centrally perform intra- well interindividual evaluation follicular CD20+ lymphoma lesion radioimmunotherapy . According , aim MERIT-NHL study prospectively identify yet unknown patient- lesion specific prognostic factor predict patient´s outcome line therapeutic modality radioimmunotherapy .</brief_summary>
	<brief_title>Evaluation Patient Lesion Specific Prognostic Factors Standard Radioimmunotherapy</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<criteria>standard radioimmunotherapy 90yttriumlabeled antiCD20antibodies treatment relapse and/or refractory follicular NHL partial remission induction chemotherapy find least one imageguided measurable lymphoma lesion existence FDGPET CTimage data 8 week treatment sign patient´s agreement RIT registry MERITNHL therapy modality standard radioimmunotherapy ( e.g . consolidation ) solely CNSlymphoma primary effusion lymphoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>radioimmunotherapy</keyword>
	<keyword>follicular non-Hodgkin´s lymphoma</keyword>
	<keyword>FDG-PET</keyword>
	<keyword>prognostic factor</keyword>
	<keyword>multicenter study</keyword>
</DOC>